Fragment-based drug design facilitates selective kinase inhibitor discovery
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pharmacology,Toxicology
Reference80 articles.
1. The protein kinase complement of the human genome;Manning;Science,2002
2. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases;Fedorov;Proc. Natl Acad. Sci. U. S. A.,2007
3. Bioinformatics toolbox for exploring protein phosphorylation network;Shi;Brief. Bioinform.,2020
4. A historical overview of protein kinases and their targeted small molecule inhibitors;Roskoski;Pharmacol. Res.,2015
5. Targeting cancer with small molecule kinase inhibitors;Zhang;Nat. Rev. Cancer,2009
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor;Current Medicinal Chemistry;2024-11
2. Peripherally targeted analgesia via AAV-mediated sensory neuron–specific inhibition of multiple pronociceptive sodium channels;Journal of Clinical Investigation;2024-05-09
3. Discovery of novel 6-p-tolyl-3-(3,4,5-trimethoxybenzyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine derivative as a potent tubulin inhibitor with promising in vivo antitumor activity;European Journal of Medicinal Chemistry;2023-08
4. FFLOM: A Flow-Based Autoregressive Model for Fragment-to-Lead Optimization;Journal of Medicinal Chemistry;2023-07-20
5. Fragment-based drug discovery supports drugging ‘undruggable’ protein–protein interactions;Trends in Biochemical Sciences;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3